How to Evolve mRNA Production and Purification in the Aftermath of COVID-19 Vaccine Development
Although mRNA therapeutics have been around in the biopharmaceutical industry for several years, the success of mRNA-based COVID-19 vaccines has fully revealed the potential of this ground-breaking technology. Given the pressure of delivering during a pandemic, manufacturers have focused primarily on safety and efficacy of mRNA vaccines and not so much on how to optimize production and purification processes for future mRNA therapeutics.
Sartorius, however, was studying these issues even before the pandemic started. Our scientists have been developing mRNA processes in our labs in Ajdovščina, Slovenia, and they have amassed a wealth of information and insights about how next-generation processes can be developed and implemented. This webinar features an exclusive panel discussion where they will discuss current approaches and bottlenecks of mRNA production and lay out their vision for truly optimized next-generation processes.
Key Learning Objectives
Review the real-world challenges our customers faced in their mRNA manufacturing efforts and how Sartorius partnered with them to develop innovative solutions
Underscore the importance of flexibility in mRNA purification and highlight some options from the Sartorius mRNA purification toolbox, such as the Oligo dT affinity monolith and PrimaS non-affinity monolith columns for the capture of mRNA
Present a method for rapid analytical monitoring of IVT reactions with CIMac® PrimaS
Meet Our Experts
Head of Technical Support and Product Manager for mRNA applications, Sartorius
Tomas holds a Master’s degree in Organic Chemistry from University College London. He joined BIA Separations, now a Sartorius company, in 2016 as an analytical scientist to support contract work and development activities. He is currently the Head of Technical Support, and Product Manager for mRNA applications.
Head of Process Development, mRNA/pDNA, Sartorius
Rok Sekirnik graduated with a degree in chemistry from the University of Oxford, where he also completed his PhD. His team at BIA Separations, now a Sartorius company, is focused on developing high-yielding, cost-effective purification approaches for pDNA and mRNA production.
Manager of Process Technology Consultants, Sartorius
Piergiuseppe Nestola, PhD, is a Manager of Process Technology Consultants at Sartorius, where he is responsible for providing scientific, technological and process leadership in the field of viral-based therapeutics.
Head of Market Entry Strategy, Viral -based Therapeutics , Sartorius
Amélie graduated from the Biotechnology Engineering Institute of Bordeaux, France (ENSTBB) and holds a degree in biotechnology engineering. Amelie in her current role is responsible for the go-to-market strategy covering both vaccine and gene therapy applications in the Viral-based Therapeutics segment at Sartorius.